Study of Durvalumab following radiation therapy in patients with stage 3 unresectable NSCLC ineligible for chemotherapy - DUART

Study identifier:D4194C00009

ClinicalTrials.gov identifier:NCT04249362

EudraCT identifier:2019-004336-31

CTIS identifier:N/A

Study Complete

Official Title

A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients with Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy

Medical condition

Non-small Cell Lung Cancer

Phase

Phase 2

Healthy volunteers

Study drug

Durvalumab

Sex

All

Actual Enrollment

102

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 26 Nov 2020

Primary Completion Date: 30 Mar 2023

Study Completion Date: 05 Dec 2023

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2024 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

1. Capable of giving signed informed consent.
2. Age ≥ 18 years at study entry.
3. Histologically or cytologically documented NSCLC with locally-advanced, unresectable Stage III disease.
4. Deemed ineligible for chemotherapy per Investigator assessment.
5. Receipt of radiation therapy that was completed within 42 days prior to first study drug administration.
6. Must have received a total dose of radiation of 40 to 66 Gy (standard or hypofractionated BED).
7. Must not have progressed following radiation therapy, as per Investigator assessed RECIST 1.1 criteria: a) Patients with measurable disease and/or nonmeasurable and/or no evidence of disease assessed at baseline by computed tomography /magnetic resonance imaging will be eligible for this study. b) Prior irradiated lesions may be considered measurable and selected as target lesions (TLs) providing they fulfill the other criteria for measurability.
8. World Health Organization/ECOG performance status of ≤2.
9. No prior exposure to immune-mediated therapy including, but not limited to, anti-CTLA-4, anti-PD-1, anti-PD-L1, and antiprogrammed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
10. Patients must have adequate organ and marrow function as defined below:
• Hemoglobin ≥ 9.0 g/dL
• Absolute neutrophil count ≥ 1.0 × 109 /L
• Platelet count ≥ 75 × 109/L
• Serum bilirubin ≤ 1.5 × the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert’s syndrome.
• Alanine aminotransferase and aspartate aminotransferase ≤ 2.5 × ULN
• Measured creatinine clearance > 30 mL/min or calculated CL > 30 mL/min as determined by Cockcroft-Gault
11. Life expectancy of greater than 12 weeks.
12. Body weight greater than 30 kg at study entry and at first study drug administration

Exclusion Criteria

1. Patients with locally-advanced NSCLC whose disease has progressed following radiation therapy.
2. Mixed small cell lung cancer and NSCLC histology.
3. History of allogeneic organ transplantation.
4. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome).
5. Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris)
6. History of another primary malignancy except for (a) malignancy treated with curative intent and with no known active disease ≥ 5 years before the first study drug administration, (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease, and c) treated carcinoma in situ without evidence of disease.
7. History of leptomeningeal carcinomatosis
8. History of active primary immunodeficiency
9. Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus
10. Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, lymphopenia, and the laboratory values defined in the inclusion criteria
11. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
12. Receipt of live attenuated vaccine within 30 days prior to the first dose of durvalumab
13. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of durvalumab.
14. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab.
15. Participation in another clinical study with an IP administered in the last 4 weeks.
16. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study
17. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
18. Patients who refuse chemotherapy by their own decision.
19. Involvement in the planning and/or conduct of the study
20. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control.
21. Judgment by the Investigator that the patient should not participate in the study
22. Genetics research study (optional):
Exclusion criteria for participation in the optional genetics research component of the study include: a) Previous allogeneic bone marrow transplant b)Nonleukocyte-depleted whole blood transfusion within 120 days of genetic sample collection.

No locations available

Arms	Assigned Interventions
Experimental: Cohort A Patients received standard radiotherapy [60 gray (Gy) ± 10% or hypofractionated BED] prior to study entry.	Drug: Durvalumab All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months. Other Name: MEDI4736
Experimental: Cohort B Patients received palliative radiotherapy [40 to < 54 Gy or hypofractionated BED] prior to study entry.	Drug: Durvalumab All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months. Other Name: MEDI4736

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]

Investigators

Principal Investigator

Dr Andrea Riccardo Filippi

Fondazione IRCCS Policlinico San Matteo